206 related articles for article (PubMed ID: 36777740)
1. Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of Omicron BQ.1, BQ.1.1, XBB and XBB.1 variants.
Popovic M
Microb Risk Anal; 2023 Apr; 23():100250. PubMed ID: 36777740
[TBL] [Abstract][Full Text] [Related]
2. XBB.1.5 Kraken cracked: Gibbs energies of binding and biosynthesis of the XBB.1.5 variant of SARS-CoV-2.
Popovic ME
Microbiol Res; 2023 May; 270():127337. PubMed ID: 36804126
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant.
Karyakarte RP; Das R; Dudhate S; Agarasen J; Pillai P; Chandankhede PM; Labhshetwar RS; Gadiyal Y; Rajmane MV; Kulkarni PP; Nizarudeen S; Joshi S; Potdar V; Karmodiya K
Cureus; 2023 Feb; 15(2):e35261. PubMed ID: 36968876
[TBL] [Abstract][Full Text] [Related]
4. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
[TBL] [Abstract][Full Text] [Related]
5. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
Ao D; He X; Hong W; Wei X
MedComm (2020); 2023 Apr; 4(2):e239. PubMed ID: 36938325
[TBL] [Abstract][Full Text] [Related]
6. Tracking SARS-CoV-2 variants during the 2023 flu season and beyond in Lebanon.
Kodsi IA; Rayes DE; Koweyes J; Khoury CA; Rahy K; Thoumi S; Chamoun M; Haddad H; Mokhbat J; Tokajian S
Virus Res; 2024 Jan; 339():199289. PubMed ID: 38036064
[TBL] [Abstract][Full Text] [Related]
7. Wastewater surveillance of SARS-CoV-2 variants in October-November 2022 in Italy: detection of XBB.1, BA.2.75 and rapid spread of the BQ.1 lineage.
La Rosa G; Brandtner D; Bonanno Ferraro G; Veneri C; Mancini P; Iaconelli M; Lucentini L; Del Giudice C; Orlandi L; ; Suffredini E
Sci Total Environ; 2023 May; 873():162339. PubMed ID: 36813191
[TBL] [Abstract][Full Text] [Related]
8. Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages - United States, January 2022-May 2023.
Ma KC; Shirk P; Lambrou AS; Hassell N; Zheng XY; Payne AB; Ali AR; Batra D; Caravas J; Chau R; Cook PW; Howard D; Kovacs NA; Lacek KA; Lee JS; MacCannell DR; Malapati L; Mathew S; Mittal N; Nagilla RR; Parikh R; Paul P; Rambo-Martin BL; Shepard SS; Sheth M; Wentworth DE; Winn A; Hall AJ; Silk BJ; Thornburg N; Kondor R; Scobie HM; Paden CR
MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(24):651-656. PubMed ID: 37319011
[TBL] [Abstract][Full Text] [Related]
9. Investigating the role of glycans in Omicron sub-lineages XBB.1.5 and XBB.1.16 binding to host receptor using molecular dynamics and binding free energy calculations.
Singh JK; Singh J; Srivastava SK
J Comput Aided Mol Des; 2023 Nov; 37(11):551-563. PubMed ID: 37542610
[TBL] [Abstract][Full Text] [Related]
10. Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
Parums DV
Med Sci Monit; 2023 Feb; 29():e939580. PubMed ID: 36722047
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters.
Halfmann PJ; Iwatsuki-Horimoto K; Kuroda M; Hirata Y; Yamayoshi S; Iida S; Uraki R; Ito M; Ueki H; Furusawa Y; Sakai-Tagawa Y; Kiso M; Armbrust T; Spyra S; Maeda K; Wang Z; Imai M; Suzuki T; Kawaoka Y
Commun Biol; 2024 Mar; 7(1):331. PubMed ID: 38491227
[TBL] [Abstract][Full Text] [Related]
12. Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ.1, BQ.1.1., and XBB.1.5 predominant omicron variants in three U.S. health systems: a retrospective cohort study.
Aggarwal NR; Beaty LE; Bennett TD; Fish LE; Jacobs JR; Mayer DA; Molina KC; Peers JL; Richardson DB; Russell S; Varela A; Webb BJ; Wynia MK; Xiao M; Carlson NE; Ginde AA
Lancet Reg Health Am; 2024 Mar; 31():100693. PubMed ID: 38500962
[TBL] [Abstract][Full Text] [Related]
13. Strain wars 2: Binding constants, enthalpies, entropies, Gibbs energies and rates of binding of SARS-CoV-2 variants.
Popovic M
Virology; 2022 May; 570():35-44. PubMed ID: 35366482
[TBL] [Abstract][Full Text] [Related]
14. Strain wars 3: Differences in infectivity and pathogenicity between Delta and Omicron strains of SARS-CoV-2 can be explained by thermodynamic and kinetic parameters of binding and growth.
Popovic M
Microb Risk Anal; 2022 Dec; 22():100217. PubMed ID: 35434234
[TBL] [Abstract][Full Text] [Related]
15. Divergent pathogenetic outcomes in BALB/c mice following Omicron subvariant infection.
Powers JM; Leist SR; Mallory ML; Yount BL; Gully KL; Zweigart MR; Bailey AB; Sheahan TP; Harkema JR; Baric RS
Virus Res; 2024 Mar; 341():199319. PubMed ID: 38224840
[TBL] [Abstract][Full Text] [Related]
16. Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5.
Entzminger KC; Fleming JK; Entzminger PD; Espinosa LY; Samadi A; Hiramoto Y; Okumura SCJ; Maruyama T
Antib Ther; 2023 Apr; 6(2):108-118. PubMed ID: 37324547
[TBL] [Abstract][Full Text] [Related]
17. Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping.
Shah M; Woo HG
Front Mol Biosci; 2023; 10():1236617. PubMed ID: 37828918
[TBL] [Abstract][Full Text] [Related]
18. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
Sullivan DJ; Franchini M; Senefeld JW; Joyner MJ; Casadevall A; Focosi D
bioRxiv; 2022 Dec; ():. PubMed ID: 36482971
[TBL] [Abstract][Full Text] [Related]
19. Strain wars 4 - Darwinian evolution through Gibbs' glasses: Gibbs energies of binding and growth explain evolution of SARS-CoV-2 from Hu-1 to BA.2.
Popovic M
Virology; 2022 Oct; 575():36-42. PubMed ID: 36057159
[TBL] [Abstract][Full Text] [Related]
20. Impact of mutations in SARS-CoV-2 recombinant sub-variant XBB.1.16 on the binding affinity with human ACE2 receptor.
Tariq SS; Zia K; Nur-E-Alam M; Nerukh D; Farafonov VS; Ul-Haq Z
J Mol Graph Model; 2024 Jun; 131():108813. PubMed ID: 38885553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
